News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
187,516 Results
Type
Article (8533)
Company Profile (118)
Press Release (178865)
Section
Business (58088)
Career Advice (364)
Deals (10481)
Drug Delivery (31)
Drug Development (35650)
Employer Resources (72)
FDA (3194)
Job Trends (4603)
News (105146)
Policy (7421)
Tag
2024 BioCapital Digital (3)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (2)
2024 Biotech Beach Standard (2)
2024 Genetown Digital (1)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (6)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (381)
Adcomms (4)
Allergies (29)
Alliances (13539)
ALS (32)
Alzheimer's disease (401)
Antibody-drug conjugate (ADC) (64)
Approvals (3222)
Artificial intelligence (73)
Autoimmune disease (8)
Automation (2)
Bankruptcy (65)
Best Places to Work (3634)
BIOSECURE Act (14)
Biosimilars (42)
Biotechnology (80)
Bladder cancer (21)
Brain cancer (14)
Breast cancer (65)
Cancer (811)
Cardiovascular disease (58)
Career advice (313)
Career pathing (21)
CAR-T (93)
Cell therapy (225)
Cervical cancer (7)
Clinical research (29864)
Collaboration (310)
Compensation (260)
Complete response letters (8)
COVID-19 (808)
CRISPR (9)
C-suite (100)
Cystic fibrosis (26)
Data (858)
Decentralized trials (1)
Denatured (12)
Depression (15)
Diabetes (63)
Diagnostics (742)
Digital health (2)
Diversity (6)
Diversity, equity & inclusion (21)
Drug discovery (30)
Drug pricing (24)
Drug shortages (3)
Duchenne muscular dystrophy (19)
Earnings (24757)
Editorial (24)
Employer branding (10)
Employer resources (63)
Events (37259)
Executive appointments (305)
FDA (3566)
Featured Employer (22)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (219)
Gene editing (25)
Generative AI (10)
Gene therapy (77)
GLP-1 (254)
Government (841)
Grass and pollen (2)
Guidances (16)
Healthcare (3049)
Huntington's disease (9)
IgA nephropathy (7)
Immunology and inflammation (36)
Indications (13)
Infectious disease (839)
Inflammatory bowel disease (53)
Inflation Reduction Act (6)
Influenza (8)
Intellectual property (38)
Interviews (58)
IPO (6148)
IRA (15)
Job creations (1093)
Job search strategy (267)
Kidney cancer (6)
Labor market (25)
Layoffs (142)
Leadership (12)
Legal (986)
Liver cancer (25)
Lung cancer (120)
Lymphoma (86)
Machine learning (2)
Management (23)
Manufacturing (114)
MASH (40)
Medical device (781)
Medtech (782)
Mergers & acquisitions (4582)
Metabolic disorders (225)
Multiple sclerosis (33)
NASH (8)
Neurodegenerative disease (27)
Neuropsychiatric disorders (7)
Neuroscience (575)
NextGen: Class of 2025 (1159)
Non-profit (314)
Northern California (1154)
Now hiring (28)
Obesity (118)
Opinion (157)
Ovarian cancer (38)
Pain (24)
Pancreatic cancer (23)
Parkinson's disease (40)
Partnered (3)
Patents (73)
Patient recruitment (40)
Peanut (15)
People (18267)
Pharmaceutical (39)
Pharmacy benefit managers (3)
Phase I (9448)
Phase II (13824)
Phase III (9798)
Pipeline (493)
Podcasts (46)
Policy (60)
Postmarket research (581)
Preclinical (3534)
Press Release (25)
Prostate cancer (26)
Psychedelics (13)
Radiopharmaceuticals (120)
Rare diseases (107)
Real estate (1313)
Recruiting (30)
Regulatory (6260)
Reports (24)
Research institute (417)
Resumes & cover letters (43)
RNA editing (1)
RSV (11)
Schizophrenia (39)
Series A (40)
Series B (25)
Service/supplier (4)
Sickle cell disease (11)
Southern California (900)
Special edition (17)
Spinal muscular atrophy (43)
Sponsored (7)
Startups (1071)
State (1)
Stomach cancer (1)
Supply chain (14)
Tariffs (9)
The Weekly (33)
United States (8429)
Vaccines (194)
Venture capitalists (16)
Webinars (7)
Weight loss (58)
Women's health (8)
Worklife (12)
Date
Today (46)
Last 7 days (322)
Last 30 days (1103)
Last 365 days (13312)
2025 (3285)
2024 (13949)
2023 (15750)
2022 (18015)
2021 (19730)
2020 (16822)
2019 (11282)
2018 (8117)
2017 (9849)
2016 (8162)
2015 (10344)
2014 (7658)
2013 (5577)
2012 (5394)
2011 (5422)
2010 (5273)
Location
Africa (207)
Alabama (19)
Alaska (1)
Arizona (20)
Arkansas (2)
Asia (14971)
Australia (1667)
California (2391)
Canada (531)
China (327)
Colorado (83)
Connecticut (96)
Delaware (72)
Europe (27568)
Florida (288)
Georgia (71)
Idaho (4)
Illinois (120)
India (7)
Indiana (80)
Iowa (6)
Japan (65)
Kansas (52)
Kentucky (7)
Maine (3)
Maryland (266)
Massachusetts (1841)
Michigan (38)
Minnesota (88)
Missouri (20)
Nebraska (6)
Nevada (8)
New Hampshire (7)
New Jersey (839)
New Mexico (9)
New York (763)
North Carolina (359)
Northern California (1154)
Ohio (67)
Oklahoma (4)
Oregon (12)
Pennsylvania (460)
Puerto Rico (5)
Rhode Island (8)
South America (263)
Southern California (900)
Tennessee (12)
Texas (260)
Utah (50)
Virginia (40)
Washington D.C. (12)
Washington State (195)
Wisconsin (10)
187,516 Results for "tc biopharm".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds
TC BioPharm plc announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,750,000 of the Company’s American Depositary Shares originally issued in December 2023 with an exercise price of £1.5814 per ADS and a term of five years.
May 6, 2024
·
4 min read
TC BioPharm to Present at the Sequire Investor Summit
TC BioPharm today announced its participation at the upcoming Sequire Investor Summit 2024 scheduled for January 23-25, 2024.
January 18, 2024
·
2 min read
Press Releases
CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
December 11, 2024
·
4 min read
Deals
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies
TC BioPharm PLC announced the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell therapies for the treatment of refractory cancers and solid tumors.
May 6, 2024
·
5 min read
Deals
TC BioPharm Announces Pricing of $3.5 Million Public Offering
TC BioPharm today announced the pricing of a public offering of 1,750,000 of its American Depositary Shares.
December 19, 2023
·
4 min read
Deals
TC BioPharm Announces Closing of $3.5 Million Public Offering
TC BioPharm today announced the closing of its previously announced public offering of 1,750,000 of its American Depositary Shares.
December 22, 2023
·
4 min read
TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe
TC BioPharm PLC announced that CEO, Bryan Kobel and Process Development Manager, Dr. Lauren Bor will be featured “Expert Speakers” at the 7th 7th CAR-TCR Summit Europe, February 27-29th in London, UK.
February 15, 2024
·
1 min read
TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement
TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced that on January 2, 2024, the Company received a written notice from The Nasdaq Stock Market.
January 4, 2024
·
2 min read
TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies
TC BioPharm today announced that the Company is undertaking a series of initiatives to reduce costs and drive efficiency in order to reduce cash burn and expand its financial runway.
January 3, 2024
·
3 min read
TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results
TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announces today that the Company has successfully completed its Safety Cohort and received positive review from the Data Safety Monitoring Board (DSMB).
November 14, 2023
·
3 min read
1 of 18,752
Next